DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for malignant myoepithelioma — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMalignant myoepithelioma maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for malignant myoepithelioma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
G protein subunit alpha q (GNAQ) — GNAQ is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet clrdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7F6I · 2.8 Å · ligand CHOLESTEROL (CLR). Experimental structure, not a prediction.
What the evidence adds up to
Malignant myoepithelioma is an exceptionally rare soft tissue tumour. A 2014 case report described an 84-year-old man with a combined myoepithelial carcinoma and myoepithelioma in the right forearm, and the authors concluded that myoepithelioma of soft tissue can progress to malignant myoepithelioma. A 1998 report documented a malignant myoepithelioma of the soft palate in a 63-year-old woman; the tumour cells stained positive for S-100 protein and vimentin, and negative for cytokeratin, GFAP, amylase, and alpha-smooth muscle actin. No treatment outcomes or survival data were given in either case.
The 2021 and 2023 abstracts are identical in wording and both state that soft tissue myoepitheliomas exhibit a wide spectrum from benignity to high-grade malignancy, with histopathological heterogeneity that makes pathological diagnosis very challenging. They note that recent molecular and genetic studies have identified unique gene fusions associated with clinicopathological features, but these have not been sufficiently elucidated. Neither abstract reports any drug therapy, response rates, or survival figures.
No abstract in this set provides any clinical trial data, treatment efficacy, or patient outcomes beyond individual case descriptions. The literature consists entirely of case reports and diagnostic reviews. What is missing is any prospective trial, any standardised treatment protocol, any data on drug response, and any patient stratification by molecular subtype. Funding for multi-centre case collection and genomic profiling would be needed before any treatment hypothesis could be tested.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Medical Case Reports · 2014 · 12 citations · open access
Combined myoepithelial carcinoma and myoepithelioma in soft tissue: a case report and review of the literature
AbstractINTRODUCTION: Soft tissue myoepithelial carcinoma and myoepithelioma are rare entities, part of myoepithelial tumors. They were incorporated into the World Health Organization classification of soft tissue tumors in 2002. Here we present an exceptional case of myoepithelial carcinoma and myoepithelioma association. To the best of our knowledge, such an association has never been reported in the literature. CASE PRESENTATION: We report a case of myoepithelial carcinoma combined with myoepithelioma occurring in the soft tissue of the right forearm of an 84-year-old Arabian man. We describe the clinical, radiological and pathological features dominated by histological polymorphism. We will also describe the proposed histological criteria of malignancy and the major role of immunohistochemistry in positive and differential diagnosis. We finally mention the therapeutic arsenal available. CONCLUSION: Through this work, we report that myoepithelioma of soft tissue can progress to malignant myoepithelioma.
Japanese Journal of Oral & Maxillofacial Surgery · 1998 · 2 citations · open access
A cace of malignant myoepithelioma of the soft palate.
AbstractA malignant myoepithelioma arising in the soft palate of a 63-year-old woman is reported. On light microscopy, the tumor was found to be composed of myoepithelial cells with clear cytoplasm and appeared to be malignant. These cells were partially encapsulated, but focally invaded the capsule and adjacent salivary gland tissue. Immunohistochemical studies showed positive staining for S-100 protein and vimentin and negative staining for cytokeratin, GFAP, amylase, and α-smooth muscle actin in the tumor cells. A review of this case and existing reports indicates that malignant myoepitheliomas exhibit a wide range of histological characteristics.
Clinical Studies & Medical Case Reports · 2021 · 0 citations · open access
AbstractBackground: Soft tissue myoepitheliomas are rare and exhibit a wide spectrum of benignity and low-to high-grade malignancy with histopathological heterogeneity, including cell morphology, nuclear atypia, proliferation patterns, and background matrices, often making pathological diagnosis very challenging.Although recent molecular and genetic studies of the genetic abnormalities, particularly unique gene fusions, have determined associations with the clinicopathological features, they have not been sufficiently elucidated. Conclusion:Malignant myoepithelioma diagnosis is very challenging owing to its rarity and clinicopathological diversity.Thus, the possibility of malignant myoepithelioma should always be considered when encountering a soft tissue malignancy that is pathologically questionable, such as the present tumor, which served as a valuable and instructive case.
Clinical Studies & Medical Case Reports · 2023 · 0 citations · open access
AbstractBackground: Soft tissue myoepitheliomas are rare and exhibit a wide spectrum of benignity and low-to high-grade malignancy with histopathological heterogeneity, including cell morphology, nuclear atypia, proliferation patterns, and background matrices, often making pathological diagnosis very challenging.Although recent molecular and genetic studies of the genetic abnormalities, particularly unique gene fusions, have determined associations with the clinicopathological features, they have not been sufficiently elucidated. Conclusion:Malignant myoepithelioma diagnosis is very challenging owing to its rarity and clinicopathological diversity.Thus, the possibility of malignant myoepithelioma should always be considered when encountering a soft tissue malignancy that is pathologically questionable, such as the present tumor, which served as a valuable and instructive case.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
